Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June

TEL AVIV, Israel, May 30, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that the Company's management will present a company overview at three upcoming scientific and investor conferences in June:

The 7th Annual LD Micro Invitational:

The 2017 Marcum MicroCap Conference:

The 27th Annual ICRS Symposium on the Cannabinoids:

About Therapix Biosciences:

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. Please visit our website for more information at www.therapixbio.com.

For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences, [email protected]

SOURCE Therapix Biosciences Ltd

Related Links

http://www.therapixbio.com